Burden and direct costs of non infectious uveitis in Spain.
OBJECTIVE
There is no updated information on epidemiology and cost of management of non infectious uveitis (NIU) in Spain. This study assessed the frequency of various types of uveítis as well as associated costs of resources used in their management.


METHODS
NIU epidemiological data and direct costs were collected from a literature search. This was complemented with consensus information from 2 expert panel meetings and data from questionnaires to ophthalmologists and rheumatologists, experts on these conditions. Healthcare resources costs were obtained from the Oblikue database, from a medical society and from approved drug prices in Spain.


RESULTS
During 2011 the estimate number of NIU was 9,398 (45% male, 70% aged 16-65 years). Incidence per type of uveitis was: acute anterior uveitis (AAU) 55%; posterior uveitis (PU) and pan-uveitis (PanU) 15% each; adult chronic anterior uveitis, paediatric chronic anterior uveitis and intermediate uveitis 5% each. Among total costs (77,834,282.10€), initial drug therapy was the highest (43,602,359.29€), followed by surgical treatment of complications (8,367,420.43€). With respect to types of uveitis, PanU (26,692,948.29€), PU (22,283,330.50€) and AAU (14,336,755.38€) showed the highest associated costs.


CONCLUSIONS
Non infectious uveitis is associated to high costs in Spain, both in its diagnosis and in its treatment. Early diagnosis and treatment should allow for substantial savings for the National Health System.
Institut Clínic d'Oftalmología, Hospital Clínic de Barcelona, Barcelona, España. Electronic address: amadan@clinic.ub.es.
Alfredo Manuel
AM
Adán-Civera
Unidad de Superficie e Inflamación Ocular, Hospital Clínico San Carlos, Madrid, España.
José Manuel
JM
Benítez-Del-Castillo
Unidad de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, España.
Ricardo
R
Blanco-Alonso
Servicio de Reumatología. Hospital Clínico Universitario San Carlos, Madrid, España.
Esperanza
E
Pato-Cour
Unidad de Espondiloartropatías, Hospital de la Vall d'Hebron, Barcelona, España.
Agustí
A
Sellas-Fernández
Departamento de Gestión Sanitaria y Relaciones Institucionales, AbbVie Farmacéutica, S.L.U., Madrid Spain.
Antonio
A
Bañares-Cañizares
D000293:Adolescent; D000328:Adult; D000368:Aged; D017281:Cost of Illness; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013030:Spain / Q000453:epidemiology; D014605:Uveitis / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology* / Q000628:therapy; D055815:Young Adult
Coste directo de la enfermedad; Direct costs of disease; España; Spain; Uveitis; Uveítis